News

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...
The stock's fall snapped a four-day winning streak.
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...
Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...
Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...
Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...
Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...
A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...